Radiofrequency ablation in Barrett's esophagus with dysplasia.

By N. Shaheen, Prateek Sharma, B. Overholt, H. Wolfsen, R. Sampliner, Kenneth K Wang, J. Galanko, M. Bronner, J. Goldblum, A. Bennett and 23 more. New England Journal of Medicine, 2009

1,335 citations recorded by the source corpus.

Subfields: Gastroenterology, Surgery

View Paper: https://www.semanticscholar.org/paper/3749d2aa7b18a6c1afc6c9ce141f959473449663

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. G. Falk
2. P. Iyer
3. L. Gerson
4. N. Ravi
5. K. Phoa
6. E. Schoon
7. G. J. Offerhaus
8. F. V. van Vilsteren

Citations in the corpus

• ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus (2015, positive): “However, the AIM-Dys-plasia trial that randomized 127 patients with dysplasia to ablation therapy compared with surveillance reported a much higher yearly progression rate of 19% in the HGD surveillance arm ( 63 ).”
• Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. (2014, background): “Of the remaining 17 progressors in the control group, 15 patients (10 high-grade dysplasia, 5 mucosal adenocarcinoma) underwent endoscopic resection plus radiofrequency ablation (n = 9; median [range], 4 resections [1-14]), or radiofrequency ablation (n = 6).”